Pharmacokinetics and metabolism of [14C] BMS-986195 in healthy male subjects

Completed

• Conditions: 10023213; Rheumatoid arthritis

• Registration Number: NL-OMON44627
• Lead Sponsor: Bristol-Myers Squibb Research and Development

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 9

Inclusion Criteria

- healthy male subjects,
- 18 - 55 years, inclusive
- BMI: 18.0 - 32.0 kg/m2, inclusive

Exclusion Criteria

Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>To assess the PK, metabolism routes and extent of elimination of a single oral<br /><br>dose of 10 mg [14C] BMS-986195 containing approximately 80 µCi (3.0 MBq) total<br /><br>radioactivity (TRA) in healthy male subjects.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To assess the safety and tolerability of a single oral dose of 10 mg [14C]<br /><br>BMS-986195 containing approximately 80 µCi (3.0 MBq) TRA.</p><br>